S

    Stoke Therapeutics Inc (STOK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $31.62
    -0.97 (-2.98%)

    Market Cap: $2.04B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(19/29)
    Avg Surprise
    +60.81%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.91
    Range$-1.02 - $-0.70
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.81+11.1%
    60d ago$-0.81+11.1%
    30d ago$-0.83+9.5%
    7d ago$-0.91+0.2%
    Current$-0.91
    Revenue Consensus
    $8M
    Range$2M - $18M
    13 analysts
    Dec 31, 2026
    EPS Consensus$-1.11
    Range$-1.44 - $-0.62
    12 analysts
    Revenue Consensus
    $14M
    Range$1M - $32M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.11---
    Sep 26EST
    		-$-0.91---
    Jun 26
    		$-0.93$-0.82-13.41%Miss-132.5%
    Mar 26
    		$-0.79$-0.82+3.66%Beat-141.6%
    Dec 25
    		$-0.97$-0.71-36.04%Miss-438.9%
    Sep 25
    		$-0.65$-0.57-14.04%Miss-38.3%
    Jun 25
    		$-0.40$-0.54+25.93%Beat+13.0%
    Mar 25
    		$1.90$-0.09+2211.11%Beat+433.3%
    Dec 24
    		$-0.18N/A+66.05%Beat+70.0%
    Sep 24
    		$-0.47$-0.54+12.96%Beat+14.5%
    Jun 24
    		$-0.46$-0.56+17.86%Beat+33.3%
    Mar 24
    		$-0.57$-0.61+6.56%Beat-7.5%
    Dec 23
    		$-0.60$-0.63+4.76%Beat+7.7%
    Sep 23
    		$-0.55$-0.64+14.06%Beat+16.7%
    Jun 23
    		$-0.69$-0.66-4.55%Miss-9.5%
    Mar 23
    		$-0.53$-0.71+25.35%Beat+19.7%
    Dec 22
    		$-0.65$-0.70+7.14%Beat+1.5%
    Sep 22
    		$-0.66$-0.68+2.94%Beat-8.2%
    Jun 22
    		$-0.63$-0.69+8.70%Beat-5.0%
    Mar 22
    		$-0.66$0.13-607.69%Miss-43.5%
    Dec 21
    		$-0.66$-0.62-6.45%Miss-57.1%
    Sep 21
    		$-0.61$-0.55-10.91%Miss-48.8%
    Jun 21
    		$-0.60$-0.46-30.43%Miss-53.8%
    Mar 21
    		$-0.46$-0.44-4.55%Miss-35.3%
    Dec 20
    		$-0.42$-0.42+0.00%Beat-366.7%
    Sep 20
    		$-0.41$-0.43+4.65%Beat-57.7%
    Jun 20
    		$-0.39$-0.36-8.33%Miss+74.7%
    Mar 20
    		$-0.34$-0.36+5.56%Beat+95.1%
    Dec 19
    		$-0.09N/A+70.00%Beat-
    Sep 19
    		$-0.26$-0.28+7.14%Beat-
    Jun 19
    		$-1.54$-1.63+5.52%Beat-
    Mar 19
    		$-6.89$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-9.47EV/EBITDA52.48x
    Price/FCF-11.55xFCF Yield-8.66%
    Profitability
    Profit Margin0.00%Operating Margin-702.00%
    ROE-61.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.69xQuick Ratio7.69x
    Trading Statistics
    Beta1.23Avg Volume961.29K
    52-Week High$40.2252-Week Low$18.80

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$32.41
    SMA 20$32.13
    SMA 50$31.19
    SMA 200$31.85
    EMA 10$32.31
    EMA 20$31.95
    EMA 50$31.46
    EMA 200$29.77

    MACD

    Line: 0.48Signal: 0.51Hist: -0.03

    ADX

    ADX: 13.6+DI: 17.8-DI: 23.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down24.0
    PSAR$30.10

    Bollinger Bands

    Upper Band$33.88
    Lower Band$30.38
    %B Position1092%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    49.3

    Momentum Oscillators

    Stoch %K63.1
    Stoch %D73.1
    Williams %R-56.9
    ROC (10d)1.1%
    Momentum0.35
    CCI (20d)-17.5
    MFI (14d)54.0

    Volatility Measures

    ATR (14d)$1.54(4.9%)
    StdDev (20d)0.88
    Hist Vol46.6%(High)

    Volume Flow

    VWAP$31.89
    OBV50.7M
    AD Line26.3M
    CMF (20d)0.275

    Volume Metrics

    Avg Vol (20d)987.2K
    Vol Ratio0.8x
    VWMA (20d)$31.89

    Pivot Points

    R3$34.36
    R2$33.77
    R1$33.18
    Pivot Point$32.59
    S1$32.00
    S2$31.41
    S3$30.82

    Advanced Oscillators

    TSI10.62
    Ultimate Osc55.3
    KST60.88

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M$3.31M
    Cost of Revenue$0$0$1.05M$0$0$0$1.11M$0$0$0$1.22M$0
    Gross Profit$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M$3.31M
    Operating Expenses$74.75M$59.65M$62.84M$53.72M$41.12M$47.33M$36.27M$34.90M$34.17M$32.59M$32.39M$30.54M
    R&D$49.50M$39.67M$41.70M$37.70M$25.86M$32.68M$23.42M$22.20M$21.14M$22.37M$21.78M$20.27M
    SG&A$25.25M$19.97M$21.15M$16.03M$15.26M$14.65M$12.85M$12.69M$13.04M$10.22M$10.61M$10.27M
    Operating Income$-65,429,000$-53,418,000$-61,439,000$-43,091,000$-27,300,000$111.24M$-13,655,000$-30,003,000$-29,342,000$-28,372,000$-29,587,000$-27,234,000
    Interest Income$3.50M$3.40M$3.62M$3.46M$3.79M$2.89M$2.97M$3.54M$3.69M$2.43M$2.59M$2.65M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-61,618,000$-50,003,000$-57,934,000$-39,625,000$-23,483,000$114.16M$-10,482,000$-26,430,000$-25,695,000$-26,374,000$-26,958,000$-24,542,000
    Income Tax Expense$0$0$0$-1,278,000$0$1.28M$0$0$0$0$0$0
    Net Income$-61,618,000$-50,003,000$-57,934,000$-38,347,000$-23,483,000$112.88M$-10,482,000$-26,430,000$-25,695,000$-26,374,000$-26,958,000$-24,542,000
    EBITDA$-65,032,000$-53,326,000$-61,695,000$-43,261,000$-26,299,000$111.25M$-13,710,000$-29,982,000$-29,131,000$-28,261,000$-29,010,000$-26,678,000
    EBIT$-65,121,000$-53,400,000$-61,549,000$-43,088,000$-27,272,000$111.27M$-13,454,000$-29,975,000$-29,390,000$-28,800,000$-29,545,000$-27,193,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about STOK

    News

    Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK

    Parkman Healthcare Partners LLC has acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) with 355,443 shares valued at approximately $11.6 million. Other institutional investors like BlackRock and Janus Henderson also increased their holdings, while company insiders sold shares to cover tax obligations. Despite missing EPS estimates, analysts maintain a "Moderate Buy" rating with an average price target of $44.25 for Stoke Therapeutics.

    MarketBeat•8/25/26•
    Somewhat-Bullish

    J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40

    J.P. Morgan has upgraded Stoke Therapeutics (STOK.US) from a Neutral to a Buy rating, while also increasing its target price from $25 to $40. This upgrade suggests a significant positive outlook for the company's stock from the investment bank.

    Moomoo•8/23/26•
    Bullish

    STOK Reinstated by JP Morgan -- Price Target Set at $40

    JP Morgan has reinstated coverage on Stoke Therapeutics (STOK) with an Overweight rating and a price target of $40.00, signaling renewed confidence in the biotechnology company's potential. Despite this optimistic analyst view, GuruFocus indicates that STOK is significantly overvalued at its current price of $32.18, with a GF Value™ of $9.65 and a mixed GF Score™ of 44/100, reflecting concerns about its profitability and valuation. Insider selling activity also suggests caution for investors.

    GuruFocus•8/21/26•
    Neutral

    Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

    JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with an "overweight" rating and a $40 price target, suggesting a potential upside of over 25%. This positive outlook aligns with a broader analyst consensus of "Moderate Buy" and an average price target of $44.25 for the company. Despite missing earnings expectations with a loss of $0.93 per share, Stoke Therapeutics exceeded revenue forecasts, driven by its development of genetic medicines like STK-001 for Dravet syndrome.

    MarketBeat•8/21/26•
    Bullish

    STOK Looks 225.6% Overvalued on GF Value™

    JPMorgan analyst Jessica Fye reinitiated coverage on Stoke Therapeutics Inc (NASDAQ: STOK) with an Overweight rating and a $40 price target, driven by confidence in its Phase III EMPEROR trial. Despite this, GuruFocus assesses STOK as 225.6% overvalued based on its GF Value™ of $9.65, with a high Price-to-Sales ratio of 70.77, weak profitability, and significant insider selling, signaling caution for investors.

    GuruFocus•8/21/26•
    Somewhat-Bearish

    Frequently Asked Questions About STOK

    Does STOK pay dividends?
    Stoke Therapeutics Inc (STOK) does not currently pay a regular dividend.
    What is STOK's market cap?
    Stoke Therapeutics Inc (STOK) has a market capitalization of $2.04B with a current stock price of $31.62.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In